nodes	percent_of_prediction	percent_of_DWPC	metapath
Etonogestrel—PGR—ovarian cancer	0.44	0.613	CbGaD
Etonogestrel—ESR1—ovarian cancer	0.278	0.387	CbGaD
Etonogestrel—PGR—corpus luteum—ovarian cancer	0.016	0.195	CbGeAlD
Etonogestrel—PGR—ovarian follicle—ovarian cancer	0.0125	0.152	CbGeAlD
Etonogestrel—ESR1—ovarian follicle—ovarian cancer	0.00977	0.119	CbGeAlD
Etonogestrel—CYP3A4—Topotecan—ovarian cancer	0.00596	0.354	CbGbCtD
Etonogestrel—PGR—oviduct—ovarian cancer	0.00549	0.0669	CbGeAlD
Etonogestrel—ESR1—oviduct—ovarian cancer	0.00429	0.0523	CbGeAlD
Etonogestrel—CYP3A4—Vinorelbine—ovarian cancer	0.0042	0.249	CbGbCtD
Etonogestrel—CYP3A4—Paclitaxel—ovarian cancer	0.00295	0.175	CbGbCtD
Etonogestrel—CYP3A4—Docetaxel—ovarian cancer	0.00213	0.127	CbGbCtD
Etonogestrel—PGR—myometrium—ovarian cancer	0.00176	0.0214	CbGeAlD
Etonogestrel—CYP3A4—Doxorubicin—ovarian cancer	0.00159	0.0945	CbGbCtD
Etonogestrel—PGR—epithelium—ovarian cancer	0.00138	0.0168	CbGeAlD
Etonogestrel—ESR1—myometrium—ovarian cancer	0.00137	0.0167	CbGeAlD
Etonogestrel—SHBG—endometrium—ovarian cancer	0.00137	0.0167	CbGeAlD
Etonogestrel—PGR—uterine cervix—ovarian cancer	0.00137	0.0167	CbGeAlD
Etonogestrel—ESR1—embryo—ovarian cancer	0.00132	0.0161	CbGeAlD
Etonogestrel—PGR—decidua—ovarian cancer	0.0013	0.0159	CbGeAlD
Etonogestrel—SHBG—gonad—ovarian cancer	0.00127	0.0155	CbGeAlD
Etonogestrel—SHBG—uterus—ovarian cancer	0.00126	0.0154	CbGeAlD
Etonogestrel—PGR—endometrium—ovarian cancer	0.00124	0.0151	CbGeAlD
Etonogestrel—PGR—uterus—ovarian cancer	0.00114	0.0139	CbGeAlD
Etonogestrel—SHBG—female reproductive system—ovarian cancer	0.00114	0.0139	CbGeAlD
Etonogestrel—ESR1—epithelium—ovarian cancer	0.00108	0.0131	CbGeAlD
Etonogestrel—SHBG—bone marrow—ovarian cancer	0.00107	0.0131	CbGeAlD
Etonogestrel—ESR1—uterine cervix—ovarian cancer	0.00107	0.013	CbGeAlD
Etonogestrel—SHBG—female gonad—ovarian cancer	0.00103	0.0126	CbGeAlD
Etonogestrel—SHBG—vagina—ovarian cancer	0.00103	0.0125	CbGeAlD
Etonogestrel—PGR—female reproductive system—ovarian cancer	0.00102	0.0125	CbGeAlD
Etonogestrel—ESR1—decidua—ovarian cancer	0.00102	0.0124	CbGeAlD
Etonogestrel—ESR1—endometrium—ovarian cancer	0.000967	0.0118	CbGeAlD
Etonogestrel—PGR—female gonad—ovarian cancer	0.000932	0.0114	CbGeAlD
Etonogestrel—PGR—vagina—ovarian cancer	0.000926	0.0113	CbGeAlD
Etonogestrel—SHBG—testis—ovarian cancer	0.000917	0.0112	CbGeAlD
Etonogestrel—ESR1—gonad—ovarian cancer	0.000897	0.0109	CbGeAlD
Etonogestrel—ESR1—uterus—ovarian cancer	0.000891	0.0109	CbGeAlD
Etonogestrel—PGR—testis—ovarian cancer	0.000826	0.0101	CbGeAlD
Etonogestrel—ESR1—female reproductive system—ovarian cancer	0.000801	0.00976	CbGeAlD
Etonogestrel—ESR1—female gonad—ovarian cancer	0.000729	0.00888	CbGeAlD
Etonogestrel—ESR1—vagina—ovarian cancer	0.000724	0.00883	CbGeAlD
Etonogestrel—Norelgestromin—PGR—ovarian cancer	0.000711	0.118	CrCbGaD
Etonogestrel—Desogestrel—PGR—ovarian cancer	0.000684	0.114	CrCbGaD
Etonogestrel—ESR1—testis—ovarian cancer	0.000646	0.00788	CbGeAlD
Etonogestrel—Norgestimate—PGR—ovarian cancer	0.00064	0.106	CrCbGaD
Etonogestrel—PGR—lymph node—ovarian cancer	0.000599	0.0073	CbGeAlD
Etonogestrel—Quinestrol—ESR1—ovarian cancer	0.000577	0.0959	CrCbGaD
Etonogestrel—ESR1—lymph node—ovarian cancer	0.000469	0.00571	CbGeAlD
Etonogestrel—CYP3A4—female reproductive system—ovarian cancer	0.000447	0.00545	CbGeAlD
Etonogestrel—Mestranol—ESR1—ovarian cancer	0.000437	0.0727	CrCbGaD
Etonogestrel—Desogestrel—ESR1—ovarian cancer	0.000432	0.0718	CrCbGaD
Etonogestrel—Norgestimate—ESR1—ovarian cancer	0.000404	0.0671	CrCbGaD
Etonogestrel—Levonorgestrel—PGR—ovarian cancer	0.000392	0.0651	CrCbGaD
Etonogestrel—Danazol—PGR—ovarian cancer	0.000357	0.0593	CrCbGaD
Etonogestrel—Norethindrone—PGR—ovarian cancer	0.000317	0.0528	CrCbGaD
Etonogestrel—Levonorgestrel—ESR1—ovarian cancer	0.000247	0.0411	CrCbGaD
Etonogestrel—Danazol—ESR1—ovarian cancer	0.000225	0.0374	CrCbGaD
Etonogestrel—Ethinyl Estradiol—ESR1—ovarian cancer	0.000208	0.0346	CrCbGaD
Etonogestrel—Testosterone—CYP1B1—ovarian cancer	0.000163	0.0272	CrCbGaD
Etonogestrel—Dermatitis—Melphalan—ovarian cancer	0.000138	0.00111	CcSEcCtD
Etonogestrel—Cough—Paclitaxel—ovarian cancer	0.000138	0.0011	CcSEcCtD
Etonogestrel—Asthenia—Vinorelbine—ovarian cancer	0.000137	0.0011	CcSEcCtD
Etonogestrel—Convulsion—Paclitaxel—ovarian cancer	0.000137	0.00109	CcSEcCtD
Etonogestrel—Migraine—Doxorubicin—ovarian cancer	0.000136	0.00109	CcSEcCtD
Etonogestrel—Affect lability—Doxorubicin—ovarian cancer	0.000136	0.00109	CcSEcCtD
Etonogestrel—Hypertension—Paclitaxel—ovarian cancer	0.000136	0.00109	CcSEcCtD
Etonogestrel—Alopecia—Docetaxel—ovarian cancer	0.000136	0.00109	CcSEcCtD
Etonogestrel—Pruritus—Vinorelbine—ovarian cancer	0.000135	0.00108	CcSEcCtD
Etonogestrel—Breast disorder—Epirubicin—ovarian cancer	0.000135	0.00108	CcSEcCtD
Etonogestrel—Mental disorder—Docetaxel—ovarian cancer	0.000135	0.00108	CcSEcCtD
Etonogestrel—Myalgia—Paclitaxel—ovarian cancer	0.000134	0.00108	CcSEcCtD
Etonogestrel—Arthralgia—Paclitaxel—ovarian cancer	0.000134	0.00108	CcSEcCtD
Etonogestrel—Anxiety—Paclitaxel—ovarian cancer	0.000134	0.00107	CcSEcCtD
Etonogestrel—Erythema—Docetaxel—ovarian cancer	0.000134	0.00107	CcSEcCtD
Etonogestrel—Malnutrition—Docetaxel—ovarian cancer	0.000134	0.00107	CcSEcCtD
Etonogestrel—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000133	0.00107	CcSEcCtD
Etonogestrel—Nausea—Topotecan—ovarian cancer	0.000133	0.00106	CcSEcCtD
Etonogestrel—Discomfort—Paclitaxel—ovarian cancer	0.000133	0.00106	CcSEcCtD
Etonogestrel—Gastritis—Epirubicin—ovarian cancer	0.000133	0.00106	CcSEcCtD
Etonogestrel—Mood swings—Doxorubicin—ovarian cancer	0.000131	0.00105	CcSEcCtD
Etonogestrel—Diarrhoea—Vinorelbine—ovarian cancer	0.000131	0.00105	CcSEcCtD
Etonogestrel—Abdominal distension—Epirubicin—ovarian cancer	0.00013	0.00104	CcSEcCtD
Etonogestrel—Nausea—Melphalan—ovarian cancer	0.00013	0.00104	CcSEcCtD
Etonogestrel—Asthma—Epirubicin—ovarian cancer	0.00013	0.00104	CcSEcCtD
Etonogestrel—Back pain—Docetaxel—ovarian cancer	0.000129	0.00104	CcSEcCtD
Etonogestrel—Anaphylactic shock—Paclitaxel—ovarian cancer	0.000129	0.00103	CcSEcCtD
Etonogestrel—Oedema—Paclitaxel—ovarian cancer	0.000129	0.00103	CcSEcCtD
Etonogestrel—Muscle spasms—Docetaxel—ovarian cancer	0.000129	0.00103	CcSEcCtD
Etonogestrel—Infection—Paclitaxel—ovarian cancer	0.000128	0.00102	CcSEcCtD
Etonogestrel—Dizziness—Vinorelbine—ovarian cancer	0.000127	0.00101	CcSEcCtD
Etonogestrel—Nervous system disorder—Paclitaxel—ovarian cancer	0.000126	0.00101	CcSEcCtD
Etonogestrel—Breast disorder—Doxorubicin—ovarian cancer	0.000125	0.001	CcSEcCtD
Etonogestrel—Skin disorder—Paclitaxel—ovarian cancer	0.000125	0.001	CcSEcCtD
Etonogestrel—Bronchitis—Epirubicin—ovarian cancer	0.000125	0.000997	CcSEcCtD
Etonogestrel—Anorexia—Paclitaxel—ovarian cancer	0.000123	0.000983	CcSEcCtD
Etonogestrel—Gastritis—Doxorubicin—ovarian cancer	0.000123	0.000982	CcSEcCtD
Etonogestrel—Vomiting—Vinorelbine—ovarian cancer	0.000122	0.000975	CcSEcCtD
Etonogestrel—PGR—Signaling by ERBB4—PIK3CD—ovarian cancer	0.000122	0.00231	CbGpPWpGaD
Etonogestrel—Dysuria—Epirubicin—ovarian cancer	0.000121	0.000969	CcSEcCtD
Etonogestrel—Rash—Vinorelbine—ovarian cancer	0.000121	0.000966	CcSEcCtD
Etonogestrel—PGR—Gene Expression—TTF1—ovarian cancer	0.000121	0.00229	CbGpPWpGaD
Etonogestrel—Dermatitis—Vinorelbine—ovarian cancer	0.000121	0.000966	CcSEcCtD
Etonogestrel—Abdominal distension—Doxorubicin—ovarian cancer	0.000121	0.000965	CcSEcCtD
Etonogestrel—Upper respiratory tract infection—Epirubicin—ovarian cancer	0.00012	0.000963	CcSEcCtD
Etonogestrel—Headache—Vinorelbine—ovarian cancer	0.00012	0.00096	CcSEcCtD
Etonogestrel—Asthma—Doxorubicin—ovarian cancer	0.00012	0.000959	CcSEcCtD
Etonogestrel—Pollakiuria—Epirubicin—ovarian cancer	0.00012	0.000957	CcSEcCtD
Etonogestrel—ESR1—Signaling mediated by p38-alpha and p38-beta—TP53—ovarian cancer	0.000119	0.00226	CbGpPWpGaD
Etonogestrel—ESR1—ATF-2 transcription factor network—CCND1—ovarian cancer	0.000119	0.00226	CbGpPWpGaD
Etonogestrel—ESR1—Regulation of Telomerase—MTOR—ovarian cancer	0.000118	0.00225	CbGpPWpGaD
Etonogestrel—Weight increased—Epirubicin—ovarian cancer	0.000118	0.000943	CcSEcCtD
Etonogestrel—ESR1—Plasma membrane estrogen receptor signaling—KRAS—ovarian cancer	0.000118	0.00224	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—HSD17B6—ovarian cancer	0.000118	0.00224	CbGpPWpGaD
Etonogestrel—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000117	0.000939	CcSEcCtD
Etonogestrel—Weight decreased—Epirubicin—ovarian cancer	0.000117	0.000938	CcSEcCtD
Etonogestrel—ESR1—Integrated Breast Cancer Pathway—BRCA2—ovarian cancer	0.000117	0.00222	CbGpPWpGaD
Etonogestrel—Cough—Docetaxel—ovarian cancer	0.000117	0.000934	CcSEcCtD
Etonogestrel—Insomnia—Paclitaxel—ovarian cancer	0.000117	0.000932	CcSEcCtD
Etonogestrel—ESR1—Aryl Hydrocarbon Receptor—MYC—ovarian cancer	0.000116	0.00221	CbGpPWpGaD
Etonogestrel—CYP3A4—Tryptophan metabolism—CYP1B1—ovarian cancer	0.000116	0.0022	CbGpPWpGaD
Etonogestrel—Convulsion—Docetaxel—ovarian cancer	0.000116	0.000928	CcSEcCtD
Etonogestrel—Paraesthesia—Paclitaxel—ovarian cancer	0.000116	0.000926	CcSEcCtD
Etonogestrel—Hypertension—Docetaxel—ovarian cancer	0.000116	0.000924	CcSEcCtD
Etonogestrel—Infestation NOS—Epirubicin—ovarian cancer	0.000115	0.000924	CcSEcCtD
Etonogestrel—Infestation—Epirubicin—ovarian cancer	0.000115	0.000924	CcSEcCtD
Etonogestrel—Bronchitis—Doxorubicin—ovarian cancer	0.000115	0.000922	CcSEcCtD
Etonogestrel—Somnolence—Paclitaxel—ovarian cancer	0.000115	0.000916	CcSEcCtD
Etonogestrel—ESR1—Integrated Pancreatic Cancer Pathway—CHEK2—ovarian cancer	0.000114	0.00217	CbGpPWpGaD
Etonogestrel—Arthralgia—Docetaxel—ovarian cancer	0.000114	0.000912	CcSEcCtD
Etonogestrel—Myalgia—Docetaxel—ovarian cancer	0.000114	0.000912	CcSEcCtD
Etonogestrel—Nausea—Vinorelbine—ovarian cancer	0.000114	0.00091	CcSEcCtD
Etonogestrel—ESR1—Aryl Hydrocarbon Receptor—MAPK1—ovarian cancer	0.000114	0.00216	CbGpPWpGaD
Etonogestrel—ESR1—Aryl Hydrocarbon Receptor—EGFR—ovarian cancer	0.000114	0.00216	CbGpPWpGaD
Etonogestrel—Dyspepsia—Paclitaxel—ovarian cancer	0.000113	0.000907	CcSEcCtD
Etonogestrel—Neuropathy peripheral—Epirubicin—ovarian cancer	0.000113	0.000906	CcSEcCtD
Etonogestrel—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000113	0.000905	CcSEcCtD
Etonogestrel—Urinary tract infection—Epirubicin—ovarian cancer	0.000112	0.000898	CcSEcCtD
Etonogestrel—Dysuria—Doxorubicin—ovarian cancer	0.000112	0.000897	CcSEcCtD
Etonogestrel—Decreased appetite—Paclitaxel—ovarian cancer	0.000112	0.000896	CcSEcCtD
Etonogestrel—Upper respiratory tract infection—Doxorubicin—ovarian cancer	0.000111	0.000891	CcSEcCtD
Etonogestrel—ESR1—Validated nuclear estrogen receptor alpha network—CCND1—ovarian cancer	0.000111	0.00211	CbGpPWpGaD
Etonogestrel—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000111	0.00089	CcSEcCtD
Etonogestrel—ESR1—AP-1 transcription factor network—CXCL8—ovarian cancer	0.000111	0.00211	CbGpPWpGaD
Etonogestrel—ESR1—Regulation of Telomerase—CDKN1B—ovarian cancer	0.000111	0.00211	CbGpPWpGaD
Etonogestrel—Fatigue—Paclitaxel—ovarian cancer	0.000111	0.000889	CcSEcCtD
Etonogestrel—ESR1—Leptin signaling pathway—ERBB2—ovarian cancer	0.000111	0.00211	CbGpPWpGaD
Etonogestrel—Pollakiuria—Doxorubicin—ovarian cancer	0.000111	0.000886	CcSEcCtD
Etonogestrel—Pain—Paclitaxel—ovarian cancer	0.00011	0.000882	CcSEcCtD
Etonogestrel—Constipation—Paclitaxel—ovarian cancer	0.00011	0.000882	CcSEcCtD
Etonogestrel—PGR—Gene Expression—NR5A1—ovarian cancer	0.00011	0.00208	CbGpPWpGaD
Etonogestrel—ESR1—Leptin signaling pathway—MTOR—ovarian cancer	0.000109	0.00208	CbGpPWpGaD
Etonogestrel—Oedema—Docetaxel—ovarian cancer	0.000109	0.000874	CcSEcCtD
Etonogestrel—Anaphylactic shock—Docetaxel—ovarian cancer	0.000109	0.000874	CcSEcCtD
Etonogestrel—Weight increased—Doxorubicin—ovarian cancer	0.000109	0.000873	CcSEcCtD
Etonogestrel—ESR1—Regulation of Telomerase—IL2—ovarian cancer	0.000109	0.00207	CbGpPWpGaD
Etonogestrel—ESR1—AP-1 transcription factor network—CDKN1B—ovarian cancer	0.000109	0.00206	CbGpPWpGaD
Etonogestrel—Infection—Docetaxel—ovarian cancer	0.000108	0.000868	CcSEcCtD
Etonogestrel—Weight decreased—Doxorubicin—ovarian cancer	0.000108	0.000868	CcSEcCtD
Etonogestrel—Sinusitis—Epirubicin—ovarian cancer	0.000108	0.000867	CcSEcCtD
Etonogestrel—ESR1—Plasma membrane estrogen receptor signaling—PIK3CA—ovarian cancer	0.000108	0.00206	CbGpPWpGaD
Etonogestrel—PGR—Signaling by ERBB4—ERBB2—ovarian cancer	0.000107	0.00204	CbGpPWpGaD
Etonogestrel—ESR1—Aryl Hydrocarbon Receptor—KRAS—ovarian cancer	0.000107	0.00204	CbGpPWpGaD
Etonogestrel—ESR1—Integrated Pancreatic Cancer Pathway—BRCA1—ovarian cancer	0.000107	0.00204	CbGpPWpGaD
Etonogestrel—Nervous system disorder—Docetaxel—ovarian cancer	0.000107	0.000857	CcSEcCtD
Etonogestrel—Infestation NOS—Doxorubicin—ovarian cancer	0.000107	0.000855	CcSEcCtD
Etonogestrel—Infestation—Doxorubicin—ovarian cancer	0.000107	0.000855	CcSEcCtD
Etonogestrel—ESR1—AP-1 transcription factor network—IL2—ovarian cancer	0.000106	0.00202	CbGpPWpGaD
Etonogestrel—Feeling abnormal—Paclitaxel—ovarian cancer	0.000106	0.00085	CcSEcCtD
Etonogestrel—Skin disorder—Docetaxel—ovarian cancer	0.000106	0.000849	CcSEcCtD
Etonogestrel—PGR—Signaling by ERBB4—PIK3CB—ovarian cancer	0.000106	0.00201	CbGpPWpGaD
Etonogestrel—PGR—Signaling by ERBB4—MTOR—ovarian cancer	0.000106	0.00201	CbGpPWpGaD
Etonogestrel—ESR1—Regulation of Telomerase—CCND1—ovarian cancer	0.000106	0.00201	CbGpPWpGaD
Etonogestrel—PGR—Generic Transcription Pathway—PARP1—ovarian cancer	0.000105	0.002	CbGpPWpGaD
Etonogestrel—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000105	0.000843	CcSEcCtD
Etonogestrel—Neuropathy peripheral—Doxorubicin—ovarian cancer	0.000105	0.000838	CcSEcCtD
Etonogestrel—Haemoglobin—Epirubicin—ovarian cancer	0.000104	0.000834	CcSEcCtD
Etonogestrel—Anorexia—Docetaxel—ovarian cancer	0.000104	0.000833	CcSEcCtD
Etonogestrel—Rhinitis—Epirubicin—ovarian cancer	0.000104	0.000832	CcSEcCtD
Etonogestrel—Urinary tract infection—Doxorubicin—ovarian cancer	0.000104	0.000831	CcSEcCtD
Etonogestrel—Haemorrhage—Epirubicin—ovarian cancer	0.000104	0.00083	CcSEcCtD
Etonogestrel—ESR1—AP-1 transcription factor network—CCND1—ovarian cancer	0.000104	0.00197	CbGpPWpGaD
Etonogestrel—Hypoaesthesia—Epirubicin—ovarian cancer	0.000103	0.000825	CcSEcCtD
Etonogestrel—Pharyngitis—Epirubicin—ovarian cancer	0.000103	0.000823	CcSEcCtD
Etonogestrel—ESR1—AP-1 transcription factor network—CTNNB1—ovarian cancer	0.000103	0.00195	CbGpPWpGaD
Etonogestrel—Urinary tract disorder—Epirubicin—ovarian cancer	0.000102	0.000819	CcSEcCtD
Etonogestrel—Urticaria—Paclitaxel—ovarian cancer	0.000102	0.000819	CcSEcCtD
Etonogestrel—Connective tissue disorder—Epirubicin—ovarian cancer	0.000102	0.000815	CcSEcCtD
Etonogestrel—Abdominal pain—Paclitaxel—ovarian cancer	0.000102	0.000815	CcSEcCtD
Etonogestrel—Body temperature increased—Paclitaxel—ovarian cancer	0.000102	0.000815	CcSEcCtD
Etonogestrel—Urethral disorder—Epirubicin—ovarian cancer	0.000102	0.000813	CcSEcCtD
Etonogestrel—ESR1—LKB1 signaling events—TP53—ovarian cancer	0.000101	0.00191	CbGpPWpGaD
Etonogestrel—ESR1—AP-1 transcription factor network—MMP9—ovarian cancer	0.000101	0.00191	CbGpPWpGaD
Etonogestrel—Sinusitis—Doxorubicin—ovarian cancer	0.0001	0.000802	CcSEcCtD
Etonogestrel—ESR1—Plasma membrane estrogen receptor signaling—HRAS—ovarian cancer	0.0001	0.0019	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—DLC1—ovarian cancer	0.0001	0.0019	CbGpPWpGaD
Etonogestrel—ESR1—AP-1 transcription factor network—PTEN—ovarian cancer	9.99e-05	0.0019	CbGpPWpGaD
Etonogestrel—Visual impairment—Epirubicin—ovarian cancer	9.99e-05	0.000799	CcSEcCtD
Etonogestrel—Musculoskeletal discomfort—Docetaxel—ovarian cancer	9.95e-05	0.000796	CcSEcCtD
Etonogestrel—PGR—Signaling by ERBB4—CDKN1B—ovarian cancer	9.94e-05	0.00189	CbGpPWpGaD
Etonogestrel—Insomnia—Docetaxel—ovarian cancer	9.88e-05	0.00079	CcSEcCtD
Etonogestrel—Paraesthesia—Docetaxel—ovarian cancer	9.8e-05	0.000785	CcSEcCtD
Etonogestrel—ESR1—Leptin signaling pathway—CCND1—ovarian cancer	9.8e-05	0.00186	CbGpPWpGaD
Etonogestrel—ESR1—ATF-2 transcription factor network—MAPK3—ovarian cancer	9.79e-05	0.00186	CbGpPWpGaD
Etonogestrel—Somnolence—Docetaxel—ovarian cancer	9.71e-05	0.000777	CcSEcCtD
Etonogestrel—Eye disorder—Epirubicin—ovarian cancer	9.69e-05	0.000775	CcSEcCtD
Etonogestrel—ESR1—Integrated Pancreatic Cancer Pathway—BRCA2—ovarian cancer	9.68e-05	0.00184	CbGpPWpGaD
Etonogestrel—Haemoglobin—Doxorubicin—ovarian cancer	9.64e-05	0.000771	CcSEcCtD
Etonogestrel—Rhinitis—Doxorubicin—ovarian cancer	9.62e-05	0.00077	CcSEcCtD
Etonogestrel—Dyspepsia—Docetaxel—ovarian cancer	9.61e-05	0.000769	CcSEcCtD
Etonogestrel—Haemorrhage—Doxorubicin—ovarian cancer	9.59e-05	0.000768	CcSEcCtD
Etonogestrel—Hypoaesthesia—Doxorubicin—ovarian cancer	9.54e-05	0.000764	CcSEcCtD
Etonogestrel—Pharyngitis—Doxorubicin—ovarian cancer	9.52e-05	0.000762	CcSEcCtD
Etonogestrel—Decreased appetite—Docetaxel—ovarian cancer	9.49e-05	0.00076	CcSEcCtD
Etonogestrel—Hypersensitivity—Paclitaxel—ovarian cancer	9.49e-05	0.00076	CcSEcCtD
Etonogestrel—Urinary tract disorder—Doxorubicin—ovarian cancer	9.47e-05	0.000758	CcSEcCtD
Etonogestrel—Gastrointestinal disorder—Docetaxel—ovarian cancer	9.43e-05	0.000754	CcSEcCtD
Etonogestrel—Connective tissue disorder—Doxorubicin—ovarian cancer	9.43e-05	0.000754	CcSEcCtD
Etonogestrel—Fatigue—Docetaxel—ovarian cancer	9.41e-05	0.000753	CcSEcCtD
Etonogestrel—Angiopathy—Epirubicin—ovarian cancer	9.4e-05	0.000753	CcSEcCtD
Etonogestrel—Urethral disorder—Doxorubicin—ovarian cancer	9.4e-05	0.000752	CcSEcCtD
Etonogestrel—ESR1—Integrated Pancreatic Cancer Pathway—CCNE1—ovarian cancer	9.38e-05	0.00178	CbGpPWpGaD
Etonogestrel—ESR1—Integrated Pancreatic Cancer Pathway—ABCB1—ovarian cancer	9.38e-05	0.00178	CbGpPWpGaD
Etonogestrel—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	9.38e-05	0.00178	CbGpPWpGaD
Etonogestrel—Immune system disorder—Epirubicin—ovarian cancer	9.36e-05	0.000749	CcSEcCtD
Etonogestrel—Pain—Docetaxel—ovarian cancer	9.34e-05	0.000747	CcSEcCtD
Etonogestrel—Constipation—Docetaxel—ovarian cancer	9.34e-05	0.000747	CcSEcCtD
Etonogestrel—ESR1—ATF-2 transcription factor network—MAPK1—ovarian cancer	9.32e-05	0.00177	CbGpPWpGaD
Etonogestrel—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	9.25e-05	0.00176	CbGpPWpGaD
Etonogestrel—Visual impairment—Doxorubicin—ovarian cancer	9.24e-05	0.00074	CcSEcCtD
Etonogestrel—Asthenia—Paclitaxel—ovarian cancer	9.24e-05	0.00074	CcSEcCtD
Etonogestrel—ESR1—Integrated Pancreatic Cancer Pathway—TYMS—ovarian cancer	9.21e-05	0.00175	CbGpPWpGaD
Etonogestrel—Alopecia—Epirubicin—ovarian cancer	9.16e-05	0.000733	CcSEcCtD
Etonogestrel—PGR—Signaling by ERBB4—PTEN—ovarian cancer	9.16e-05	0.00174	CbGpPWpGaD
Etonogestrel—ESR1—Aryl Hydrocarbon Receptor—HRAS—ovarian cancer	9.13e-05	0.00173	CbGpPWpGaD
Etonogestrel—Pruritus—Paclitaxel—ovarian cancer	9.11e-05	0.000729	CcSEcCtD
Etonogestrel—Mental disorder—Epirubicin—ovarian cancer	9.08e-05	0.000727	CcSEcCtD
Etonogestrel—ESR1—Gene Expression—WDR77—ovarian cancer	9.03e-05	0.00172	CbGpPWpGaD
Etonogestrel—Erythema—Epirubicin—ovarian cancer	9.02e-05	0.000722	CcSEcCtD
Etonogestrel—Malnutrition—Epirubicin—ovarian cancer	9.02e-05	0.000722	CcSEcCtD
Etonogestrel—Feeling abnormal—Docetaxel—ovarian cancer	9e-05	0.00072	CcSEcCtD
Etonogestrel—Eye disorder—Doxorubicin—ovarian cancer	8.96e-05	0.000717	CcSEcCtD
Etonogestrel—Gastrointestinal pain—Docetaxel—ovarian cancer	8.93e-05	0.000715	CcSEcCtD
Etonogestrel—ESR1—Validated nuclear estrogen receptor alpha network—MYC—ovarian cancer	8.92e-05	0.0017	CbGpPWpGaD
Etonogestrel—Flatulence—Epirubicin—ovarian cancer	8.89e-05	0.000712	CcSEcCtD
Etonogestrel—Tension—Epirubicin—ovarian cancer	8.86e-05	0.000709	CcSEcCtD
Etonogestrel—Ethinyl Estradiol—ABCB1—ovarian cancer	8.85e-05	0.0147	CrCbGaD
Etonogestrel—ESR1—Plasma membrane estrogen receptor signaling—AKT1—ovarian cancer	8.84e-05	0.00168	CbGpPWpGaD
Etonogestrel—Diarrhoea—Paclitaxel—ovarian cancer	8.81e-05	0.000705	CcSEcCtD
Etonogestrel—Nervousness—Epirubicin—ovarian cancer	8.76e-05	0.000701	CcSEcCtD
Etonogestrel—ESR1—Regulation of Telomerase—MAPK3—ovarian cancer	8.74e-05	0.00166	CbGpPWpGaD
Etonogestrel—Back pain—Epirubicin—ovarian cancer	8.73e-05	0.000699	CcSEcCtD
Etonogestrel—Angiopathy—Doxorubicin—ovarian cancer	8.7e-05	0.000696	CcSEcCtD
Etonogestrel—Muscle spasms—Epirubicin—ovarian cancer	8.68e-05	0.000694	CcSEcCtD
Etonogestrel—Immune system disorder—Doxorubicin—ovarian cancer	8.66e-05	0.000693	CcSEcCtD
Etonogestrel—Body temperature increased—Docetaxel—ovarian cancer	8.63e-05	0.000691	CcSEcCtD
Etonogestrel—Abdominal pain—Docetaxel—ovarian cancer	8.63e-05	0.000691	CcSEcCtD
Etonogestrel—Dizziness—Paclitaxel—ovarian cancer	8.52e-05	0.000682	CcSEcCtD
Etonogestrel—Norethindrone—ABCB1—ovarian cancer	8.51e-05	0.0141	CrCbGaD
Etonogestrel—ESR1—Regulation of Telomerase—MYC—ovarian cancer	8.5e-05	0.00162	CbGpPWpGaD
Etonogestrel—Alopecia—Doxorubicin—ovarian cancer	8.48e-05	0.000678	CcSEcCtD
Etonogestrel—ESR1—Leptin signaling pathway—STAT3—ovarian cancer	8.46e-05	0.00161	CbGpPWpGaD
Etonogestrel—ESR1—Signaling by ERBB4—IL6ST—ovarian cancer	8.45e-05	0.00161	CbGpPWpGaD
Etonogestrel—Mental disorder—Doxorubicin—ovarian cancer	8.4e-05	0.000672	CcSEcCtD
Etonogestrel—Ill-defined disorder—Epirubicin—ovarian cancer	8.37e-05	0.00067	CcSEcCtD
Etonogestrel—Erythema—Doxorubicin—ovarian cancer	8.35e-05	0.000668	CcSEcCtD
Etonogestrel—Malnutrition—Doxorubicin—ovarian cancer	8.35e-05	0.000668	CcSEcCtD
Etonogestrel—ESR1—Regulation of Telomerase—MAPK1—ovarian cancer	8.32e-05	0.00158	CbGpPWpGaD
Etonogestrel—ESR1—Regulation of Telomerase—EGFR—ovarian cancer	8.31e-05	0.00158	CbGpPWpGaD
Etonogestrel—ESR1—AP-1 transcription factor network—MYC—ovarian cancer	8.3e-05	0.00158	CbGpPWpGaD
Etonogestrel—Flatulence—Doxorubicin—ovarian cancer	8.23e-05	0.000658	CcSEcCtD
Etonogestrel—Tension—Doxorubicin—ovarian cancer	8.19e-05	0.000656	CcSEcCtD
Etonogestrel—Vomiting—Paclitaxel—ovarian cancer	8.19e-05	0.000655	CcSEcCtD
Etonogestrel—PGR—Signaling by ERBB4—NRAS—ovarian cancer	8.17e-05	0.00155	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—BCL9—ovarian cancer	8.15e-05	0.00155	CbGpPWpGaD
Etonogestrel—Malaise—Epirubicin—ovarian cancer	8.14e-05	0.000651	CcSEcCtD
Etonogestrel—Rash—Paclitaxel—ovarian cancer	8.12e-05	0.00065	CcSEcCtD
Etonogestrel—Dermatitis—Paclitaxel—ovarian cancer	8.11e-05	0.000649	CcSEcCtD
Etonogestrel—Nervousness—Doxorubicin—ovarian cancer	8.11e-05	0.000649	CcSEcCtD
Etonogestrel—ESR1—Leptin signaling pathway—MAPK3—ovarian cancer	8.08e-05	0.00154	CbGpPWpGaD
Etonogestrel—Back pain—Doxorubicin—ovarian cancer	8.08e-05	0.000646	CcSEcCtD
Etonogestrel—Headache—Paclitaxel—ovarian cancer	8.07e-05	0.000646	CcSEcCtD
Etonogestrel—Hypersensitivity—Docetaxel—ovarian cancer	8.04e-05	0.000644	CcSEcCtD
Etonogestrel—Muscle spasms—Doxorubicin—ovarian cancer	8.03e-05	0.000642	CcSEcCtD
Etonogestrel—Cough—Epirubicin—ovarian cancer	7.87e-05	0.00063	CcSEcCtD
Etonogestrel—Asthenia—Docetaxel—ovarian cancer	7.83e-05	0.000627	CcSEcCtD
Etonogestrel—PGR—Signaling by ERBB4—MAPK3—ovarian cancer	7.82e-05	0.00149	CbGpPWpGaD
Etonogestrel—Convulsion—Epirubicin—ovarian cancer	7.82e-05	0.000626	CcSEcCtD
Etonogestrel—Hypertension—Epirubicin—ovarian cancer	7.79e-05	0.000623	CcSEcCtD
Etonogestrel—Ill-defined disorder—Doxorubicin—ovarian cancer	7.75e-05	0.00062	CcSEcCtD
Etonogestrel—Pruritus—Docetaxel—ovarian cancer	7.72e-05	0.000618	CcSEcCtD
Etonogestrel—ESR1—Leptin signaling pathway—MAPK1—ovarian cancer	7.69e-05	0.00146	CbGpPWpGaD
Etonogestrel—Myalgia—Epirubicin—ovarian cancer	7.68e-05	0.000615	CcSEcCtD
Etonogestrel—Arthralgia—Epirubicin—ovarian cancer	7.68e-05	0.000615	CcSEcCtD
Etonogestrel—Anxiety—Epirubicin—ovarian cancer	7.66e-05	0.000613	CcSEcCtD
Etonogestrel—Nausea—Paclitaxel—ovarian cancer	7.65e-05	0.000612	CcSEcCtD
Etonogestrel—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	7.63e-05	0.000611	CcSEcCtD
Etonogestrel—ESR1—Generic Transcription Pathway—YAP1—ovarian cancer	7.62e-05	0.00145	CbGpPWpGaD
Etonogestrel—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	7.6e-05	0.00144	CbGpPWpGaD
Etonogestrel—Discomfort—Epirubicin—ovarian cancer	7.59e-05	0.000607	CcSEcCtD
Etonogestrel—Malaise—Doxorubicin—ovarian cancer	7.53e-05	0.000603	CcSEcCtD
Etonogestrel—ESR1—Integrated Breast Cancer Pathway—CDH1—ovarian cancer	7.51e-05	0.00143	CbGpPWpGaD
Etonogestrel—Diarrhoea—Docetaxel—ovarian cancer	7.47e-05	0.000598	CcSEcCtD
Etonogestrel—PGR—Signaling by ERBB4—MAPK1—ovarian cancer	7.44e-05	0.00142	CbGpPWpGaD
Etonogestrel—PGR—Signaling by ERBB4—EGFR—ovarian cancer	7.44e-05	0.00141	CbGpPWpGaD
Etonogestrel—ESR1—Regulation of nuclear SMAD2/3 signaling—MYC—ovarian cancer	7.39e-05	0.0014	CbGpPWpGaD
Etonogestrel—Oedema—Epirubicin—ovarian cancer	7.36e-05	0.000589	CcSEcCtD
Etonogestrel—Anaphylactic shock—Epirubicin—ovarian cancer	7.36e-05	0.000589	CcSEcCtD
Etonogestrel—Infection—Epirubicin—ovarian cancer	7.32e-05	0.000586	CcSEcCtD
Etonogestrel—Cough—Doxorubicin—ovarian cancer	7.29e-05	0.000583	CcSEcCtD
Etonogestrel—Convulsion—Doxorubicin—ovarian cancer	7.23e-05	0.000579	CcSEcCtD
Etonogestrel—Nervous system disorder—Epirubicin—ovarian cancer	7.22e-05	0.000578	CcSEcCtD
Etonogestrel—Dizziness—Docetaxel—ovarian cancer	7.22e-05	0.000578	CcSEcCtD
Etonogestrel—Hypertension—Doxorubicin—ovarian cancer	7.21e-05	0.000577	CcSEcCtD
Etonogestrel—ESR1—ATF-2 transcription factor network—IL6—ovarian cancer	7.16e-05	0.00136	CbGpPWpGaD
Etonogestrel—Skin disorder—Epirubicin—ovarian cancer	7.15e-05	0.000572	CcSEcCtD
Etonogestrel—ESR1—Signaling by ERBB4—PIK3CD—ovarian cancer	7.14e-05	0.00136	CbGpPWpGaD
Etonogestrel—Myalgia—Doxorubicin—ovarian cancer	7.11e-05	0.000569	CcSEcCtD
Etonogestrel—Arthralgia—Doxorubicin—ovarian cancer	7.11e-05	0.000569	CcSEcCtD
Etonogestrel—ESR1—Gene Expression—TTF1—ovarian cancer	7.08e-05	0.00135	CbGpPWpGaD
Etonogestrel—Anxiety—Doxorubicin—ovarian cancer	7.08e-05	0.000567	CcSEcCtD
Etonogestrel—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	7.06e-05	0.000565	CcSEcCtD
Etonogestrel—PGR—Signaling by ERBB4—KRAS—ovarian cancer	7.03e-05	0.00134	CbGpPWpGaD
Etonogestrel—Discomfort—Doxorubicin—ovarian cancer	7.02e-05	0.000562	CcSEcCtD
Etonogestrel—Anorexia—Epirubicin—ovarian cancer	7.02e-05	0.000562	CcSEcCtD
Etonogestrel—Vomiting—Docetaxel—ovarian cancer	6.94e-05	0.000556	CcSEcCtD
Etonogestrel—ESR1—Signaling Pathways—HSD17B6—ovarian cancer	6.9e-05	0.00131	CbGpPWpGaD
Etonogestrel—Rash—Docetaxel—ovarian cancer	6.88e-05	0.000551	CcSEcCtD
Etonogestrel—Dermatitis—Docetaxel—ovarian cancer	6.88e-05	0.00055	CcSEcCtD
Etonogestrel—Headache—Docetaxel—ovarian cancer	6.84e-05	0.000547	CcSEcCtD
Etonogestrel—ESR1—AP-1 transcription factor network—TP53—ovarian cancer	6.82e-05	0.0013	CbGpPWpGaD
Etonogestrel—Anaphylactic shock—Doxorubicin—ovarian cancer	6.81e-05	0.000545	CcSEcCtD
Etonogestrel—Oedema—Doxorubicin—ovarian cancer	6.81e-05	0.000545	CcSEcCtD
Etonogestrel—Infection—Doxorubicin—ovarian cancer	6.77e-05	0.000542	CcSEcCtD
Etonogestrel—ESR1—Integrated Pancreatic Cancer Pathway—APC—ovarian cancer	6.76e-05	0.00129	CbGpPWpGaD
Etonogestrel—Musculoskeletal discomfort—Epirubicin—ovarian cancer	6.71e-05	0.000537	CcSEcCtD
Etonogestrel—Nervous system disorder—Doxorubicin—ovarian cancer	6.68e-05	0.000535	CcSEcCtD
Etonogestrel—Insomnia—Epirubicin—ovarian cancer	6.66e-05	0.000533	CcSEcCtD
Etonogestrel—ESR1—Generic Transcription Pathway—PGR—ovarian cancer	6.65e-05	0.00126	CbGpPWpGaD
Etonogestrel—Skin disorder—Doxorubicin—ovarian cancer	6.62e-05	0.00053	CcSEcCtD
Etonogestrel—Paraesthesia—Epirubicin—ovarian cancer	6.61e-05	0.000529	CcSEcCtD
Etonogestrel—Somnolence—Epirubicin—ovarian cancer	6.55e-05	0.000524	CcSEcCtD
Etonogestrel—Anorexia—Doxorubicin—ovarian cancer	6.5e-05	0.00052	CcSEcCtD
Etonogestrel—Nausea—Docetaxel—ovarian cancer	6.49e-05	0.000519	CcSEcCtD
Etonogestrel—Dyspepsia—Epirubicin—ovarian cancer	6.48e-05	0.000519	CcSEcCtD
Etonogestrel—PGR—Signaling by ERBB4—PIK3CA—ovarian cancer	6.46e-05	0.00123	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—DOK1—ovarian cancer	6.45e-05	0.00123	CbGpPWpGaD
Etonogestrel—ESR1—Gene Expression—NR5A1—ovarian cancer	6.43e-05	0.00122	CbGpPWpGaD
Etonogestrel—Decreased appetite—Epirubicin—ovarian cancer	6.4e-05	0.000512	CcSEcCtD
Etonogestrel—Gastrointestinal disorder—Epirubicin—ovarian cancer	6.36e-05	0.000509	CcSEcCtD
Etonogestrel—Fatigue—Epirubicin—ovarian cancer	6.35e-05	0.000508	CcSEcCtD
Etonogestrel—ESR1—Signaling by ERBB4—ERBB2—ovarian cancer	6.3e-05	0.0012	CbGpPWpGaD
Etonogestrel—Constipation—Epirubicin—ovarian cancer	6.3e-05	0.000504	CcSEcCtD
Etonogestrel—Pain—Epirubicin—ovarian cancer	6.3e-05	0.000504	CcSEcCtD
Etonogestrel—ESR1—Integrated Breast Cancer Pathway—MTOR—ovarian cancer	6.25e-05	0.00119	CbGpPWpGaD
Etonogestrel—PGR—Gene Expression—YAP1—ovarian cancer	6.25e-05	0.00119	CbGpPWpGaD
Etonogestrel—ESR1—AP-1 transcription factor network—IL6—ovarian cancer	6.24e-05	0.00119	CbGpPWpGaD
Etonogestrel—ESR1—Signaling by ERBB4—MTOR—ovarian cancer	6.22e-05	0.00118	CbGpPWpGaD
Etonogestrel—ESR1—Signaling by ERBB4—PIK3CB—ovarian cancer	6.22e-05	0.00118	CbGpPWpGaD
Etonogestrel—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	6.21e-05	0.000497	CcSEcCtD
Etonogestrel—ESR1—Generic Transcription Pathway—PARP1—ovarian cancer	6.19e-05	0.00118	CbGpPWpGaD
Etonogestrel—ESR1—Leptin signaling pathway—HRAS—ovarian cancer	6.17e-05	0.00117	CbGpPWpGaD
Etonogestrel—Insomnia—Doxorubicin—ovarian cancer	6.16e-05	0.000493	CcSEcCtD
Etonogestrel—Paraesthesia—Doxorubicin—ovarian cancer	6.12e-05	0.00049	CcSEcCtD
Etonogestrel—Feeling abnormal—Epirubicin—ovarian cancer	6.07e-05	0.000486	CcSEcCtD
Etonogestrel—PGR—Signaling Pathways—PPP1CC—ovarian cancer	6.06e-05	0.00115	CbGpPWpGaD
Etonogestrel—Somnolence—Doxorubicin—ovarian cancer	6.06e-05	0.000485	CcSEcCtD
Etonogestrel—PGR—Generic Transcription Pathway—ESR1—ovarian cancer	6.05e-05	0.00115	CbGpPWpGaD
Etonogestrel—Gastrointestinal pain—Epirubicin—ovarian cancer	6.02e-05	0.000482	CcSEcCtD
Etonogestrel—Dyspepsia—Doxorubicin—ovarian cancer	6e-05	0.00048	CcSEcCtD
Etonogestrel—PGR—Signaling by ERBB4—HRAS—ovarian cancer	5.98e-05	0.00114	CbGpPWpGaD
Etonogestrel—Decreased appetite—Doxorubicin—ovarian cancer	5.92e-05	0.000474	CcSEcCtD
Etonogestrel—ESR1—Regulation of Telomerase—AKT1—ovarian cancer	5.89e-05	0.00112	CbGpPWpGaD
Etonogestrel—Gastrointestinal disorder—Doxorubicin—ovarian cancer	5.88e-05	0.000471	CcSEcCtD
Etonogestrel—Fatigue—Doxorubicin—ovarian cancer	5.87e-05	0.00047	CcSEcCtD
Etonogestrel—ESR1—Signaling Pathways—DLC1—ovarian cancer	5.87e-05	0.00112	CbGpPWpGaD
Etonogestrel—Urticaria—Epirubicin—ovarian cancer	5.85e-05	0.000468	CcSEcCtD
Etonogestrel—ESR1—Signaling by ERBB4—CDKN1B—ovarian cancer	5.84e-05	0.00111	CbGpPWpGaD
Etonogestrel—Pain—Doxorubicin—ovarian cancer	5.83e-05	0.000466	CcSEcCtD
Etonogestrel—Constipation—Doxorubicin—ovarian cancer	5.83e-05	0.000466	CcSEcCtD
Etonogestrel—Body temperature increased—Epirubicin—ovarian cancer	5.82e-05	0.000466	CcSEcCtD
Etonogestrel—Abdominal pain—Epirubicin—ovarian cancer	5.82e-05	0.000466	CcSEcCtD
Etonogestrel—ESR1—Integrated Breast Cancer Pathway—CASP3—ovarian cancer	5.75e-05	0.00109	CbGpPWpGaD
Etonogestrel—PGR—Signaling by ERBB4—IL6—ovarian cancer	5.72e-05	0.00109	CbGpPWpGaD
Etonogestrel—Feeling abnormal—Doxorubicin—ovarian cancer	5.62e-05	0.000449	CcSEcCtD
Etonogestrel—ESR1—Integrated Breast Cancer Pathway—CCND1—ovarian cancer	5.6e-05	0.00106	CbGpPWpGaD
Etonogestrel—Gastrointestinal pain—Doxorubicin—ovarian cancer	5.57e-05	0.000446	CcSEcCtD
Etonogestrel—ESR1—Integrated Breast Cancer Pathway—CTNNB1—ovarian cancer	5.54e-05	0.00105	CbGpPWpGaD
Etonogestrel—ESR1—Leptin signaling pathway—AKT1—ovarian cancer	5.45e-05	0.00104	CbGpPWpGaD
Etonogestrel—Hypersensitivity—Epirubicin—ovarian cancer	5.43e-05	0.000434	CcSEcCtD
Etonogestrel—Urticaria—Doxorubicin—ovarian cancer	5.41e-05	0.000433	CcSEcCtD
Etonogestrel—ESR1—Integrated Breast Cancer Pathway—PTEN—ovarian cancer	5.4e-05	0.00103	CbGpPWpGaD
Etonogestrel—Abdominal pain—Doxorubicin—ovarian cancer	5.39e-05	0.000431	CcSEcCtD
Etonogestrel—Body temperature increased—Doxorubicin—ovarian cancer	5.39e-05	0.000431	CcSEcCtD
Etonogestrel—ESR1—Signaling by ERBB4—PTEN—ovarian cancer	5.37e-05	0.00102	CbGpPWpGaD
Etonogestrel—Asthenia—Epirubicin—ovarian cancer	5.28e-05	0.000423	CcSEcCtD
Etonogestrel—PGR—Signaling by ERBB4—AKT1—ovarian cancer	5.28e-05	0.001	CbGpPWpGaD
Etonogestrel—ESR1—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	5.25e-05	0.000998	CbGpPWpGaD
Etonogestrel—Pruritus—Epirubicin—ovarian cancer	5.21e-05	0.000417	CcSEcCtD
Etonogestrel—ESR1—Regulation of nuclear SMAD2/3 signaling—AKT1—ovarian cancer	5.12e-05	0.000974	CbGpPWpGaD
Etonogestrel—PGR—Gene Expression—PARP1—ovarian cancer	5.07e-05	0.000965	CbGpPWpGaD
Etonogestrel—Diarrhoea—Epirubicin—ovarian cancer	5.04e-05	0.000403	CcSEcCtD
Etonogestrel—Hypersensitivity—Doxorubicin—ovarian cancer	5.02e-05	0.000402	CcSEcCtD
Etonogestrel—Asthenia—Doxorubicin—ovarian cancer	4.89e-05	0.000391	CcSEcCtD
Etonogestrel—ESR1—Integrated Breast Cancer Pathway—VEGFA—ovarian cancer	4.88e-05	0.000928	CbGpPWpGaD
Etonogestrel—Dizziness—Epirubicin—ovarian cancer	4.87e-05	0.00039	CcSEcCtD
Etonogestrel—ESR1—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	4.86e-05	0.000924	CbGpPWpGaD
Etonogestrel—Pruritus—Doxorubicin—ovarian cancer	4.82e-05	0.000386	CcSEcCtD
Etonogestrel—ESR1—Signaling by ERBB4—NRAS—ovarian cancer	4.79e-05	0.000911	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—BCL9—ovarian cancer	4.79e-05	0.00091	CbGpPWpGaD
Etonogestrel—ESR1—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	4.77e-05	0.000906	CbGpPWpGaD
Etonogestrel—Testosterone—ABCB1—ovarian cancer	4.69e-05	0.00779	CrCbGaD
Etonogestrel—Vomiting—Epirubicin—ovarian cancer	4.68e-05	0.000375	CcSEcCtD
Etonogestrel—Diarrhoea—Doxorubicin—ovarian cancer	4.66e-05	0.000373	CcSEcCtD
Etonogestrel—Rash—Epirubicin—ovarian cancer	4.64e-05	0.000372	CcSEcCtD
Etonogestrel—Dermatitis—Epirubicin—ovarian cancer	4.64e-05	0.000371	CcSEcCtD
Etonogestrel—ESR1—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	4.64e-05	0.000882	CbGpPWpGaD
Etonogestrel—Headache—Epirubicin—ovarian cancer	4.61e-05	0.000369	CcSEcCtD
Etonogestrel—ESR1—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	4.59e-05	0.000873	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—HDAC6—ovarian cancer	4.59e-05	0.000873	CbGpPWpGaD
Etonogestrel—ESR1—Signaling by ERBB4—MAPK3—ovarian cancer	4.59e-05	0.000873	CbGpPWpGaD
Etonogestrel—Dizziness—Doxorubicin—ovarian cancer	4.51e-05	0.000361	CcSEcCtD
Etonogestrel—ESR1—Integrated Breast Cancer Pathway—MYC—ovarian cancer	4.49e-05	0.000854	CbGpPWpGaD
Etonogestrel—ESR1—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	4.48e-05	0.000851	CbGpPWpGaD
Etonogestrel—ESR1—Integrated Breast Cancer Pathway—MAPK1—ovarian cancer	4.39e-05	0.000835	CbGpPWpGaD
Etonogestrel—ESR1—Integrated Breast Cancer Pathway—EGFR—ovarian cancer	4.39e-05	0.000835	CbGpPWpGaD
Etonogestrel—Nausea—Epirubicin—ovarian cancer	4.37e-05	0.00035	CcSEcCtD
Etonogestrel—ESR1—Signaling by ERBB4—MAPK1—ovarian cancer	4.37e-05	0.000831	CbGpPWpGaD
Etonogestrel—ESR1—Signaling by ERBB4—EGFR—ovarian cancer	4.37e-05	0.00083	CbGpPWpGaD
Etonogestrel—Vomiting—Doxorubicin—ovarian cancer	4.33e-05	0.000347	CcSEcCtD
Etonogestrel—Rash—Doxorubicin—ovarian cancer	4.3e-05	0.000344	CcSEcCtD
Etonogestrel—Dermatitis—Doxorubicin—ovarian cancer	4.29e-05	0.000344	CcSEcCtD
Etonogestrel—Headache—Doxorubicin—ovarian cancer	4.27e-05	0.000342	CcSEcCtD
Etonogestrel—ESR1—Integrated Breast Cancer Pathway—KRAS—ovarian cancer	4.15e-05	0.000789	CbGpPWpGaD
Etonogestrel—ESR1—Signaling by ERBB4—KRAS—ovarian cancer	4.13e-05	0.000785	CbGpPWpGaD
Etonogestrel—PGR—Gene Expression—PPP2R1A—ovarian cancer	4.12e-05	0.000783	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—YAP1—ovarian cancer	4.06e-05	0.000773	CbGpPWpGaD
Etonogestrel—Nausea—Doxorubicin—ovarian cancer	4.05e-05	0.000324	CcSEcCtD
Etonogestrel—ESR1—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	4.04e-05	0.000769	CbGpPWpGaD
Etonogestrel—CYP3A4—Biological oxidations—CYP1B1—ovarian cancer	4.04e-05	0.000768	CbGpPWpGaD
Etonogestrel—CYP3A4—Metapathway biotransformation—CYP1B1—ovarian cancer	3.98e-05	0.000757	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—XIAP—ovarian cancer	3.98e-05	0.000757	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—SMARCA4—ovarian cancer	3.88e-05	0.000738	CbGpPWpGaD
Etonogestrel—ESR1—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	3.83e-05	0.000727	CbGpPWpGaD
Etonogestrel—ESR1—Signaling by ERBB4—PIK3CA—ovarian cancer	3.79e-05	0.000721	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—EREG—ovarian cancer	3.79e-05	0.00072	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—DOK1—ovarian cancer	3.78e-05	0.000719	CbGpPWpGaD
Etonogestrel—ESR1—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	3.72e-05	0.000707	CbGpPWpGaD
Etonogestrel—ESR1—Integrated Breast Cancer Pathway—TP53—ovarian cancer	3.69e-05	0.000701	CbGpPWpGaD
Etonogestrel—ESR1—Gene Expression—YAP1—ovarian cancer	3.67e-05	0.000697	CbGpPWpGaD
Etonogestrel—ESR1—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	3.64e-05	0.000692	CbGpPWpGaD
Etonogestrel—ESR1—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	3.64e-05	0.000692	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—PPP1CC—ovarian cancer	3.56e-05	0.000676	CbGpPWpGaD
Etonogestrel—ESR1—Signaling by ERBB4—HRAS—ovarian cancer	3.51e-05	0.000667	CbGpPWpGaD
Etonogestrel—ESR1—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	3.44e-05	0.000653	CbGpPWpGaD
Etonogestrel—ESR1—Signaling by ERBB4—IL6—ovarian cancer	3.36e-05	0.000638	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—PARP1—ovarian cancer	3.3e-05	0.000627	CbGpPWpGaD
Etonogestrel—ESR1—Gene Expression—PGR—ovarian cancer	3.2e-05	0.000609	CbGpPWpGaD
Etonogestrel—ESR1—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	3.16e-05	0.0006	CbGpPWpGaD
Etonogestrel—PGR—Generic Transcription Pathway—MYC—ovarian cancer	3.15e-05	0.000599	CbGpPWpGaD
Etonogestrel—ESR1—Integrated Breast Cancer Pathway—AKT1—ovarian cancer	3.11e-05	0.000592	CbGpPWpGaD
Etonogestrel—ESR1—Signaling by ERBB4—AKT1—ovarian cancer	3.1e-05	0.000589	CbGpPWpGaD
Etonogestrel—ESR1—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	3.06e-05	0.000581	CbGpPWpGaD
Etonogestrel—ESR1—Gene Expression—PARP1—ovarian cancer	2.98e-05	0.000566	CbGpPWpGaD
Etonogestrel—PGR—Gene Expression—ESR1—ovarian cancer	2.91e-05	0.000554	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—HDAC6—ovarian cancer	2.7e-05	0.000512	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—PPP2R1A—ovarian cancer	2.68e-05	0.000509	CbGpPWpGaD
Etonogestrel—ESR1—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	2.58e-05	0.00049	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—NME2—ovarian cancer	2.46e-05	0.000468	CbGpPWpGaD
Etonogestrel—ESR1—Gene Expression—PPP2R1A—ovarian cancer	2.42e-05	0.000459	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—YAP1—ovarian cancer	2.39e-05	0.000453	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—XIAP—ovarian cancer	2.34e-05	0.000444	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—SMARCA4—ovarian cancer	2.28e-05	0.000433	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—EREG—ovarian cancer	2.22e-05	0.000423	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—TERT—ovarian cancer	2.13e-05	0.000404	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—PGR—ovarian cancer	2.08e-05	0.000396	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—CAV1—ovarian cancer	1.97e-05	0.000374	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—PARP1—ovarian cancer	1.94e-05	0.000368	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—ESR1—ovarian cancer	1.9e-05	0.00036	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—IL6ST—ovarian cancer	1.86e-05	0.000354	CbGpPWpGaD
Etonogestrel—ESR1—Generic Transcription Pathway—MYC—ovarian cancer	1.85e-05	0.000351	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—APC—ovarian cancer	1.79e-05	0.000341	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—PIK3CG—ovarian cancer	1.79e-05	0.000341	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—CYTB—ovarian cancer	1.59e-05	0.000302	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—PIK3CD—ovarian cancer	1.57e-05	0.000299	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—PPP2R1A—ovarian cancer	1.57e-05	0.000299	CbGpPWpGaD
Etonogestrel—PGR—Gene Expression—MAPK3—ovarian cancer	1.56e-05	0.000296	CbGpPWpGaD
Etonogestrel—PGR—Gene Expression—MYC—ovarian cancer	1.52e-05	0.000288	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—ERBB2—ovarian cancer	1.39e-05	0.000264	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—BRIP1—ovarian cancer	1.39e-05	0.000264	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—PPP1CC—ovarian cancer	1.39e-05	0.000264	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—MTOR—ovarian cancer	1.37e-05	0.000261	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—PIK3CB—ovarian cancer	1.37e-05	0.000261	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—CXCL8—ovarian cancer	1.32e-05	0.000251	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—CDKN1B—ovarian cancer	1.29e-05	0.000245	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—CASP3—ovarian cancer	1.26e-05	0.00024	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—IL2—ovarian cancer	1.26e-05	0.00024	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—TERT—ovarian cancer	1.25e-05	0.000237	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—CCND1—ovarian cancer	1.23e-05	0.000234	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—CTNNB1—ovarian cancer	1.22e-05	0.000231	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—MMP9—ovarian cancer	1.19e-05	0.000227	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—PTEN—ovarian cancer	1.19e-05	0.000225	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—CAV1—ovarian cancer	1.15e-05	0.000219	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—IL6ST—ovarian cancer	1.09e-05	0.000208	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—VEGFA—ovarian cancer	1.07e-05	0.000204	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—STAT3—ovarian cancer	1.06e-05	0.000202	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—NRAS—ovarian cancer	1.06e-05	0.000201	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—APC—ovarian cancer	1.05e-05	0.0002	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—PIK3CG—ovarian cancer	1.05e-05	0.0002	CbGpPWpGaD
Etonogestrel—PGR—Gene Expression—AKT1—ovarian cancer	1.05e-05	0.0002	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—MAPK3—ovarian cancer	1.01e-05	0.000193	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—MYC—ovarian cancer	9.86e-06	0.000187	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—MAPK1—ovarian cancer	9.64e-06	0.000183	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—EGFR—ovarian cancer	9.64e-06	0.000183	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—YAP1—ovarian cancer	9.3e-06	0.000177	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—PIK3CD—ovarian cancer	9.24e-06	0.000176	CbGpPWpGaD
Etonogestrel—ESR1—Gene Expression—MAPK3—ovarian cancer	9.15e-06	0.000174	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—KRAS—ovarian cancer	9.11e-06	0.000173	CbGpPWpGaD
Etonogestrel—ESR1—Gene Expression—MYC—ovarian cancer	8.9e-06	0.000169	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—PIK3CA—ovarian cancer	8.37e-06	0.000159	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—ERBB2—ovarian cancer	8.16e-06	0.000155	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—TP53—ovarian cancer	8.09e-06	0.000154	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—MTOR—ovarian cancer	8.06e-06	0.000153	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—PIK3CB—ovarian cancer	8.06e-06	0.000153	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—CXCL8—ovarian cancer	7.74e-06	0.000147	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—HRAS—ovarian cancer	7.74e-06	0.000147	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—FASN—ovarian cancer	7.58e-06	0.000144	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—CDKN1B—ovarian cancer	7.56e-06	0.000144	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—SLC5A5—ovarian cancer	7.46e-06	0.000142	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—CASP3—ovarian cancer	7.41e-06	0.000141	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—IL6—ovarian cancer	7.41e-06	0.000141	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—IL2—ovarian cancer	7.4e-06	0.000141	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—CCND1—ovarian cancer	7.21e-06	0.000137	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—SLC2A1—ovarian cancer	7.2e-06	0.000137	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—CTNNB1—ovarian cancer	7.14e-06	0.000136	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—MMP9—ovarian cancer	7e-06	0.000133	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—PTEN—ovarian cancer	6.96e-06	0.000132	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—CYP1B1—ovarian cancer	6.9e-06	0.000131	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—AKT1—ovarian cancer	6.84e-06	0.00013	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—VEGFA—ovarian cancer	6.29e-06	0.00012	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—STAT3—ovarian cancer	6.23e-06	0.000118	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—NRAS—ovarian cancer	6.21e-06	0.000118	CbGpPWpGaD
Etonogestrel—ESR1—Gene Expression—AKT1—ovarian cancer	6.17e-06	0.000117	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	6.12e-06	0.000116	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—MAPK3—ovarian cancer	5.95e-06	0.000113	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—MYC—ovarian cancer	5.79e-06	0.00011	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—ABCB1—ovarian cancer	5.69e-06	0.000108	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—MAPK1—ovarian cancer	5.66e-06	0.000108	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—EGFR—ovarian cancer	5.66e-06	0.000108	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—TYMS—ovarian cancer	5.58e-06	0.000106	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—KRAS—ovarian cancer	5.35e-06	0.000102	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—PIK3CA—ovarian cancer	4.91e-06	9.34e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—TP53—ovarian cancer	4.75e-06	9.03e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—HRAS—ovarian cancer	4.54e-06	8.64e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—CAV1—ovarian cancer	4.5e-06	8.55e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—IL6—ovarian cancer	4.35e-06	8.27e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—PIK3CG—ovarian cancer	4.1e-06	7.79e-05	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—AKT1—ovarian cancer	4.01e-06	7.63e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—PIK3CD—ovarian cancer	3.6e-06	6.85e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—PIK3CB—ovarian cancer	3.14e-06	5.97e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—PTEN—ovarian cancer	2.71e-06	5.16e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—PIK3CA—ovarian cancer	1.91e-06	3.64e-05	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—AKT1—ovarian cancer	1.56e-06	2.97e-05	CbGpPWpGaD
